Not a good buy right now: price is in a confirmed downtrend and just broke below the near-term support (S1=8.548) with bearish momentum (MACD worsening).
Options positioning is bullish (very low put/call ratios) but that alone isn’t enough to fade the prevailing downtrend without a catalyst.
Fundamentals remain weak (2025/Q3 revenue -56% YoY, gross margin down), so there’s no clear fundamental floor for an impatient entry.
Momentum: MACD histogram at -0.146 and negatively expanding → downside momentum is strengthening.
RSI: RSI_6 = 25.858 suggests oversold conditions; however, oversold can persist in strong downtrends.
Levels: Current price 8.27 is below S1 (8.548); next support S2 at 7.889. Key pivot resistance overhead at 9.613, then R1 10.679.
Market context: SP500 down -0.71% today adds mild risk-off pressure.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Skew bullish—open interest put/call ratio 0.36 and volume put/call ratio 0.1 imply calls dominate.
Activity: Today’s option volume is elevated vs 30-day average (19.7x), signaling speculative attention.
Volatility: IV_30d 107.47 vs historical vol 66.47 → options are pricing large moves; IV percentile ~45 (mid-range vs its own history).
Positioning detail: Call OI 9,355 vs Put OI 3,368 supports the bullish tilt, but it can also reflect hedging/positioning rather than directional conviction.
Technical Summary
Sell
3
Buy
12
Positive Catalysts
increases odds of a short-term bounce if selling pressure eases.
Neutral/Negative Catalysts
increases risk of a move toward S2 (7.
before any durable base forms.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: 38.84M, down -56.39% YoY (major top-line contraction).
Profitability: Net income improved to -80.76M (+43.18% YoY, i.e., smaller loss), and EPS improved to -1.45 (+34.26% YoY).
Gross margin: 67.04%, down -22.52% YoY, indicating weaker unit economics/mix.
Takeaway: Cost/loss metrics are improving, but the growth trend is negative and remains the biggest fundamental headwind.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent action (2026-01-08): TD Cowen kept Buy but lowered price target to $12 (from $14 per the dataset).
Wall Street pro view (pros): Maintained Buy suggests belief in multi-year upside framework.
Wall Street con view (cons): Price target cut highlights uncertainty and reduced confidence in near-term execution/recovery.
Wall Street analysts forecast DNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNA is 12 USD with a low forecast of 12 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast DNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNA is 12 USD with a low forecast of 12 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
2 Sell
Moderate Sell
Current: 8.320
Low
12
Averages
12
High
12
Current: 8.320
Low
12
Averages
12
High
12
TD Cowen
Buy
downgrade
$142 -> $12
AI Analysis
2026-01-08
Reason
TD Cowen
Price Target
$142 -> $12
AI Analysis
2026-01-08
downgrade
Buy
Reason
TD Cowen lowered the firm's price target on Ginkgo Bioworks to $12 from $142 and keeps a Buy rating on the shares. The firm adjusted price targets in the diagnostic tools group group as part of a Q4 preview. Investor sentiment continues to inflect upward with 2026 guidance updates "key for positioning within the sector recovery," the analyst tells investors in a research note. TD is most positive on stocks "with clear multi-year frameworks and multiple avenues for upside to derisked growth assumptions."
TD Cowen
Buy
downgrade
$14 -> $12
2026-01-08
Reason
TD Cowen
Price Target
$14 -> $12
2026-01-08
downgrade
Buy
Reason
TD Cowen lowered the firm's price target on Ginkgo Bioworks to $12 from $14 and keeps a Buy rating on the shares. The firm adjusted price targets in the diagnostic tools group group as part of a Q4 preview. Investor sentiment continues to inflect upward with 2026 guidance updates "key for positioning within the sector recovery," the analyst tells investors in a research note. TD is most positive on stocks "with clear multi-year frameworks and multiple avenues for upside to derisked growth assumptions."
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DNA
